Sign in
CompletedNo phase

Assessment of Maternal and Fetal Serum Biomarkers in Women With Pre-eclampsia

Key facts

Who runs it
SHAHLA KAREEM ALALAF
Where
Iraq1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
204 people enrolled
Started
13 Dec 2024
Ended
12 Jul 2025
Type of study
Observational, 2 groups
Record updated
16 July 2025

Who can take part

Age
18 years to 45 years
Sex
Women only

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Age group 18-45 years
  • Gestational age of 26-41 weeks at the time of diagnosis for preeclampsia
  • Delivered vaginally or abdominally
  • Being of any parity (para 1 and more)
  • Pregnancy being singleton or multiple pregnancies
  • Willingness to provide informed consent

Who cannot take part

  • The lady on medications that can affect inflammatory markers or blood pressure
  • Pregnant woman having chronic hypertension
  • Having Diabetes mellitus
  • Pregnant with fetal anomalies
  • Refused to involve in the research

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The findings of markers of placental dysfunction in women with preeclampsia may suggest that these biomarkers may be useful tools for early detection of preeclampsia

The 2 groups in the trial

  • Women with Preeclampsia

    This group will comprise pregnant women having preeclampsia who are scheduled to undergo either vaginal or cesarean delivery. Their blood and their newborn blood will be collected and tested for a panel of inflammatory markers. This research aims to explore the potential association between maternal and neonatal inflammatory profiles and the development of preeclampsia, as well as its impact on pregnancy outcomes. By examining these markers, we hope to gain a better understanding of the underlying inflammatory mechanisms involved in preeclampsia.

  • Normotensive pregnant women

    This group will consist of normotensive pregnant women during delivery who are scheduled to have their blood and their newborn blood tested for a panel of inflammatory markers and responses to inflammatory markers. One of the aims of this research is to investigate the potential association between maternal and neonatal inflammatory profiles in normotensive pregnancy in comparison to women with preeclampsia and their newborn By examining these markers

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Assessment of Maternal and Fetal Serum Soluble Fms-like Tyrosine Kinase-1, Seromucoid, and Protein-bound Hexose in Women With Pre-eclampsia: A Case-control Study
Record updated
16 July 2025